Načítá se...
Rofecoxib and Clinically Significant Upper and Lower GI Events Revisited based on documents from recent litigation.
BACKGROUND: Based on published data, it is widely believed and cited that rofecoxib use is associated with approximately a 50% reduction in significant gastrointestinal complications such as bleeding. METHODS: Data made available as part of litigation, including the VIGOR trial and an Azlheimers’ st...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2011
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3203315/ https://ncbi.nlm.nih.gov/pubmed/21986300 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MAJ.0b013e3182113658 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|